RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
Boston, January 25, 2017 – Cytonome/ST, LLC announces it has signed the first application specific agreement to license its proprietary GigaSortTM Technology for commercial scale cell therapy production. A premier pharmaceutical company has signed on for rights to use the technology for their explicit disease indication. They will manufacture a critical cell therapy to address one of the major diseases afflicting aging populations globally.
